CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease.

Melanoma patients who got an mRNA vaccine for the virus saw median survival times double.

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Vaccine manufacturing is challenged by stringent global regulations, essential for ensuring safety and efficacy, with ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The Deputy Minister of Science, Technology and Innovation, Dr Nomalungelo Gina, will deliver the keynote address at the opening of Biovac’s new product development laboratory in Cape Town on Thursday, ...

The official opening will be headlined by Dr Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, who ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...